Loading patent…
AssigneeQingdao Kangmingbei Jian Biopharmaceutical Co., Ltd.
InventorsWenhua XU, Xiaomin WANG, Yan TANG, Xiao XU, Xiaoying KONG, Jiaxu SONG, Mengyu ZHANG, Xin MA, Yiwei XU, Junlin LV, Nailong PAN, Zhen SHANG, Liang ZHANG, Dan HAN
Estimating the term…
The present invention belongs to the field of biomedical technology, and specifically relates to a new application for piR-hsa-164586 and MYH9, based on the interaction between piR-hsa-164586 and MYH9: piR-hsa-164586 regulates the expression of MYH9 and promotes the metastasis of NSCLC, piR-hsa-164586 and MYH9 can be used as a therapeutic target for NSCLC, and have become a potential therapeutic drug, wherein the MYH9 is obtained by RNA pulldown assay and verified by protein mass spectrometry, molecular docking and RIP assays, the piR-hsa-164586 can positively regulate the expression of MYH9, and verified by performed qRT-PCR, western blotting and tissue immunofluorescence staining assays on the piR-hsa-164586 NC group, piR-hsa-164586 KD group, and piR-hsa-164586 OE group. The interaction between piR-hsa-164586 and MYH9 can up-regulate the expression of MYH9 in NSCLC cell lines, the verification experiment process was confirmed by Transwell experiment after knockdown of piR-hsa-164586 and MYH9 respectively.
A new application for piR-hsa-164586 and MYH9, wherein the piR-hsa-164586 and MYH9 as a therapeutic target for NSCLC.
Dependencies are inferred from the claim text.